PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩100 per share · Prices as of the 2026-10-02 close
BC World Pharm, which leans on drug delivery system technology, shows stable revenue but operating and net profit that swing quarter to quarter, leaving earnings consistency as the key watch item.
Annual revenue stayed range-bound between KRW 72.7bn and KRW 75.8bn from 2022-2025, while operating profit fell sharply from KRW 6.37bn in 2023 to KRW 1.50bn in 2024 before a modest recovery to KRW 2.00bn in 2025.
Net income attributable to owners posted losses of KRW -4.43bn in 2024 and KRW -4.90bn in 2025 for two straight years, even as operating cash flow remained positive every year.
The operating margin improved to 9.1% in Q1 2026 and net income turned positive, but by Q2 2026 the operating margin dropped back to 0.7% and net income swung to a loss again.
Building on its DDS core technologies, the company rolled out newly licensed products such as the Qutenza patch and 4SEAL hemostat, along with a new P-CAB gastrointestinal drug and the hypertension drug Ambaro OD.
In September 2026 the company was selected for a government-backed program to discover antibiotic-resistance candidate substances using AI and quantum-mechanics-based drug design, though the work remains at an early research stage.
BC World Pharm is a Korea-based generic and incrementally modified drug maker specializing in drug delivery system (DDS) technology.
The company states it holds four core DDS platforms: long-acting injectable microspheres, nanosuspension, gastro-retentive drug delivery, and orally disintegrating sustained-release tablets.
Its product lines span anesthetics and pain management drugs, cardiovascular drugs, antibiotics, and other prescription drugs; in the first quarter of 2026 the revenue mix was 42% antibiotics, 25% other prescription drugs, 18% anesthetics/pain drugs and 15% cardiovascular drugs, shifting in the second quarter to 33% other prescription drugs and 33% antibiotics.
Manufacturing takes place at the Yeoju plant (tablets, liquid injectables, lyophilized injectables) and the Wonju plant (dedicated to carbapenem antibiotics), both certified under EU/US GMP and domestic KGMP standards, and both also run contract development and manufacturing (CDMO) business.
Subsidiary BC World Healthcare is pursuing the launch of a treatment for severe pediatric drooling and a bridgehead for overseas expansion of carbapenem antibiotics.
Recently the company secured exclusive domestic distribution of the Qutenza pain patch from Germany's Grunenthal GmbH and exclusive supply of the 4SEAL hemostat from the UK's Grena, while launching the new hypertension drug Ambaro OD and a P-CAB class gastrointestinal treatment.
Exports have expanded mainly across Asian markets such as Vietnam, Thailand, Myanmar and the Philippines, and in April 2025 the company set a goal of raising exports to 30% of total revenue within three years.
In the domestic prescription drug market it competes alongside larger generic and incrementally modified drug makers such as Yuhan Corp, Chong Kun Dang, GC Biopharma and Hanmi Pharmaceutical, and is classified as a small-to-mid-size specialty player by scale.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩20.4B | ₩1.8B | 8.9% |
| 2025Q3 | ₩19.3B | ₩100M | 0.8% |
| 2025Q4 | ₩20.3B | ₩700M | 3.5% |
| 2026Q1 | ₩19.8B | ₩1.8B | 9.1% |
| 2026Q2 | ₩21B | ₩100M | 0.7% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩72.7B | ₩1.9B | ₩300M | 2.6% | 0.4% | 136.1% |
| 2023 | ₩75.1B | ₩6.4B | ₩2.6B | 8.5% | 3.2% | 130.5% |
| 2024 | ₩74.8B | ₩1.5B | -₩4.4B | 2.0% | −5.8% | 132.0% |
| 2025 | ₩75.8B | ₩2B | -₩4.9B | 2.6% | −6.9% | 143.9% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
BC World Pharm's annual revenue was KRW 72.7bn in 2022, KRW 75.1bn in 2023, KRW 74.8bn in 2024, and KRW 75.8bn in 2025, staying largely flat in the KRW 72-76bn range over four years.
Operating profit surged from KRW 1.86bn (2.6% margin) in 2022 to KRW 6.37bn (8.5%) in 2023, then reverted to KRW 1.50bn (2.0%) in 2024 before a modest recovery to KRW 2.00bn (2.6%) in 2025.
By contrast, net income attributable to owners was positive at KRW 0.28bn in 2022 and KRW 2.63bn in 2023, but posted losses of KRW -4.43bn in 2024 and KRW -4.90bn in 2025 for two consecutive years, diverging from the operating profit trend.
This gap between operating profit and net income stands in contrast to operating cash flow, which stayed positive every year from 2022 to 2025 in a range of KRW 4.0-10.9bn, suggesting non-operating items weighed on the bottom line.
On a quarterly basis, margins compressed sharply from KRW 20.4bn revenue and KRW 1.82bn operating profit (8.9%) in Q2 2025 to KRW 19.3bn revenue and KRW 0.15bn operating profit (0.8%) in Q3 2025, before recovering somewhat to KRW 20.3bn revenue and KRW 0.72bn operating profit (3.5%) in Q4 2025.
In Q1 2026 revenue was KRW 19.8bn with operating profit of KRW 1.81bn (9.1%) and net income turning positive at KRW 0.33bn, but in Q2 2026, despite revenue rising to KRW 21.0bn, operating profit fell sharply to KRW 0.15bn (0.7%) and net income swung back to a loss of KRW -1.13bn.
Industry tallies show the company's Q1 2026 operating margin at 9.11%, an improvement of 13.49 percentage points year-on-year, with the net margin improving by 15.81 percentage points.
However, in the preceding Q1 2025, consolidated revenue had fallen 2.9% year-on-year while operating losses widened 44.2% and net losses widened 32.6% amid intensifying competition and cost pressure, so the recent improvement can be read as a rebound from a low base.
Quarterly results thus fluctuate considerably with product mix and one-off factors, and on an annual basis the company has yet to reproduce the higher margins seen in 2023.
Korea's prescription drug market features intense competition among generic and incrementally modified drug makers, and results are directly exposed to national health insurance drug-pricing policy.
The DDS segment in which BC World Pharm operates seeks differentiation from originator drugs through formulation technologies such as long-acting injectables and nanosuspension, an area where competition is intensifying as multiple domestic pharma companies pursue similar technologies.
The government runs R&D programs supporting AI-based drug candidate discovery, and in September 2026 BC World Pharm was selected as the lead research institution for a 'promising SME technology - AI candidate substance discovery' program to identify antibiotic-resistance candidate substances.
The project, run jointly with Qnova, aims to secure lead compounds that simultaneously target pan-beta-lactamase and penicillin-binding proteins, and currently remains at an early research stage for candidate discovery.
Specialty prescription areas such as antibiotics and anesthetics/pain drugs are heavily dependent on hospital prescriptions, and have historically shown sensitivity to healthcare policy shifts.
In the CMO/CDMO segment, the company continues efforts to expand contract manufacturing agreements with global pharma companies by leveraging the EU-GMP, cGMP and KGMP certifications at its Yeoju and Wonju plants.
On the export front, plans are underway to broaden reach from core Asian markets into Japan, Canada, and the US/Latin America, a growth strategy shared broadly among domestic small-to-mid-size pharma companies.
The company has designated 2026 as its 20th anniversary since re-founding, holding a commemorative ceremony in June, and has laid out this year's growth strategy around timely new product launches, cost innovation, facility and process automation, and building an R&D foundation through AI and open innovation.
Subsidiary BC World Healthcare has set goals of successfully launching a treatment for severe pediatric drooling and securing a bridgehead for the global expansion of carbapenem antibiotics.
In 2026 the company has already launched the hypertension drug Ambaro OD (May) and a P-CAB class gastrointestinal treatment (May), while expanding its lineup through exclusive domestic distribution and supply agreements for the Qutenza pain patch and 4SEAL hemostat.
The company also stated it is rebuilding its ERP system and pursuing organizational efficiency improvements.
On the R&D front, it was selected in September 2026 for a Ministry of SMEs and Startups program to discover antibiotic-resistance candidate substances with Qnova using AI and quantum-mechanics-based drug design, with plans to advance any secured lead compounds toward non-clinical development as a new pipeline.
Exports are being pursued through expansion beyond core Asian markets into Japan and through discussions with a top-tier Canadian pharma company, with the company having previously stated a goal of reaching 30% export share of revenue within three years.
However, the timing and scale of revenue contribution from these new products and pipeline items have not yet been quantified in disclosures, warranting confirmation through future quarterly results and business reports.
Because net income attributable to owners has remained in loss territory over the most recent four quarters (Q3 2025 through Q2 2026), price-to-earnings based comparisons are limited. The price-to-book ratio sits below 1x, meaning shares trade at a discount to net asset value.
The company has maintained small annual cash dividends, though the dividend yield is assessed as unremarkable relative to sector averages. Compared with the elevated 8.5% operating margin seen in 2023, the profit recovery of the past two years has yet to reach that level.
Given the small market capitalization and limited liquidity typical of a small-cap KOSDAQ name, valuation metrics can swing meaningfully around earnings releases or contract disclosures.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The company states it holds four core DDS platforms: long-acting injectables, nanosuspension, gastro-retentive systems, and orally disintegrating sustained-release tablets. Building on this, it runs EU-GMP and KGMP certified manufacturing alongside CDMO business at its Yeoju and Wonju plants.
Its ongoing strategy is to secure competitiveness through formulation-technology differentiation rather than plain generics.
In 2026 the company launched the hypertension drug Ambaro OD and a P-CAB class gastrointestinal treatment, and secured exclusive domestic distribution and supply rights for Germany's Grunenthal Qutenza pain patch and the UK's Grena 4SEAL hemostat.
Subsidiary BC World Healthcare is also pursuing the launch of a severe pediatric drooling treatment and global expansion of carbapenem antibiotics. This range of new products and licenses carries potential to diversify revenue sources.
Operating cash flow stayed positive every year from 2022 through 2025, ranging from KRW 4.0bn to KRW 10.9bn. This held true even in 2024-2025 when net income was in loss territory. This suggests relatively stable cash-generating capacity relative to reported profit.
Net income attributable to owners posted losses of KRW -4.43bn in 2024 and KRW -4.90bn in 2025, two consecutive years in the red. In 2026 the pattern continued, with a profit of KRW 0.33bn in Q1 followed by a loss of KRW -1.13bn in Q2, swinging between profit and loss each quarter. Low predictability of earnings is a burden factor.
The 2025 operating margin of 2.6% falls well short of the 8.5% seen in 2023. Quarterly margins have also swung widely, from 0.7% in Q2 2026 to 9.1% in Q1 2026. The company has yet to establish a stable margin structure.
From 2022 to 2025, annual revenue remained confined to a range between KRW 72.7bn and KRW 75.8bn, without a box breakout. No clear top-line growth has materialized. Revenue contribution from the new-product and export expansion strategy has not yet been confirmed in disclosures.
Domestic prescription drugs are directly affected by national health insurance pricing policy, and intensifying generic/incrementally modified drug competition can pressure margins. There has been a past instance where reduced hospital visits amid medical sector disputes affected results. Sensitivity of earnings to policy shifts is relatively high.
While the company is pursuing greater export share, the current export ratio and pace of progress have not been disclosed in detail. Currency fluctuations and changes in contract terms with overseas partners could affect results. The possibility that targeted export expansion does not proceed as planned cannot be ruled out.
The AI-based antibiotic-resistance R&D program selected in September 2026 remains at an early research stage for candidate substance discovery. The commercialization timing and success of new pipeline items such as the pediatric drooling treatment are also not yet confirmed. Given the early-stage nature of the R&D, commercialization entails time and uncertainty.
Watch the Q3 2026 quarterly report to see whether the operating margin recovers from the Q2 pullback and whether the pattern of alternating net profit/loss continues.
This is the point to check, via business reports and IR materials, how much revenue newly launched products such as the Qutenza patch, 4SEAL hemostat, P-CAB gastrointestinal drug and Ambaro OD are contributing.
Check the interim progress of the AI-based antibiotic-resistance candidate discovery R&D program selected in September 2026 and the results of its collaboration with Qnova.
This is the point to check progress toward the company's stated goal of reaching 30% export share within three years, via export-ratio disclosures in the annual business report.
This is the point to monitor disclosures and news regarding subsidiary BC World Healthcare's launch of a severe pediatric drooling treatment and overseas expansion of carbapenem antibiotics.
BC World Pharm is a small-to-mid-size pharmaceutical company with core DDS technology and a diversified product portfolio, with annual revenue stable in the KRW 72-76bn range.
However, the operating margin fell from 8.5% in 2023 to the low single digits in 2024-2025, and net income attributable to owners posted losses for two consecutive years, with volatility swinging between profit and loss on a quarterly basis.
The profit improvement seen in Q1 2026 came alongside a low base effect, and margins compressed sharply again in Q2, so the durability of the improvement remains to be confirmed.
Pipeline expansion moves continued into 2026 with new product launches, licensing deals, and selection for an AI-based R&D program, but the timing and scale of revenue contribution have not been quantified in disclosures.
Operating cash flow stayed positive every year despite net losses, indicating relatively resilient cash-generating capacity.
Going forward, future quarterly results, the revenue contribution of new products, and progress toward the export expansion target are likely to be the key variables in assessing earnings reliability.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.